Chronic Obstructive Pulmonary Disease – Landscape & Forecast – Disease Landscape & Forecast (G7)

The chronic obstructive pulmonary disease (COPD) market continues to gradually shift away from LABA/ICS FDCs toward LABA/LAMA FDCs and LABA/LAMA/ICS FDCs, but current and emerging generics are expected to have an impact on this trend. Some generic LABA/ICS FDCs and LAMAs have already launched in the United States and Europe, and more will reach the market in the coming years, together with generics for triple therapies. Although physicians will welcome additional treatment options for this chronic disease as a result of the development and launch of novel drug classes, including biologics (e.g.,IL-4 / IL-13 inhibitors, IL-5 inhibitors, IL-33 inhibitors, and TSLP inhibitors) and novel nebulized therapies (e.g., PDE3/4 inhibitors), significant unmet need remains for therapies that can repair lung tissue and/or halt disease progression.

Questions answered

• What impact will LABA/LAMA/ICS FDCs have on the market share of other inhaled therapies (e.g., LABA/LAMA FDCs, LABA/ICS FDCs)
• What is the use and overall acceptance of newly launched biologics dupilumab and mepolizumab?
• What are key opinion leaders’ insights on current treatment options (e.g., GSK’s Trelegy, Advair, Breo, Nucala; GSK / Innoviva’s Anoro; BI’s Spiriva, Stiolto / Spiolto; AstraZeneca’s Breztri / Trixeo, Symbicort; Sanofi / Regeneron dupilumab)? What factors drive physicians’ treatment decisions?
• Which emerging therapies have the most potential for uptake? Will nebulized therapies be accepted? Will the use of IL-33 and TSLP inhibitors be accepted for COPD? How will the launch of these and other biologics influence the COPD market?
• How will the market evolve over the 10-year forecast period?
• What are the unmet needs for COPD?

Geography: United States, EU5, Japan

Primary research: Country-specific interviews with thought-leading pulmonologists; supported by survey data collected for this and other Clarivate research

Epidemiology: Number of drug-treated COPD patients by country, segmented by severity (mild to moderate, severe to very severe)

Forecast: 10-year, annualized, drug-level sales and patient share of key COPD therapies through 2034, segmented by brands / generics and epidemiological subpopulations (mild to moderate, severe to very severe)

Drug treatments: Coverage of key current and late-phase emerging therapies

Product description

Disease Landscape & Forecast offers comprehensive market intelligence with world-class epidemiology, keen insight into current and emerging therapies, and drug forecasts supported by detailed primary and secondary research, enabling you to:

• Optimize your long-term disease and development strategy.
• Quantify market potential for your pipeline assets and those of your competitors.
• Understand a disease from top to bottom, including key patient populations, the current and future therapeutic landscape, and the evolving market trajectory.
• Gauge the commercial outlook and impact of key market events.